Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Neurology | Family Medicine | Genetic Disease
Search Medical Condition
Epilepsy Clinical Trials
A listing of Epilepsy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (256) clinical trials
Double blind, randomized, historical control study of the safety and efficacy of Eslicarbazepine Acetate Monotherapy in subjects with partial epilepsy not well controlled by current antiepileptic drugs
This research study will examine the safety and efficacy of Eslicarbazepine Acetate therapy at a dose of 1600 mg/day in subjects with partial epilepsy not well controlled on their current anti epileptic regimen. Patient Inclusion Criteria: 16 -70 years of age Documented diagnosis of epilepsy w/EEG done in prior 10 ...
Pediatric Seizures Study
Clinical Research Center of Nevada is enrolling volunteers in a research study for pediatric seizures.
Focal-Onset Seizures – Medication-Resistant Epilepsy
A research study is evaluating an investigational medication when added to standard therapy for adults with medication-resistant epilepsy who experience focal-onset seizures.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal ...
A Phase 2a, Safety, Tolerability, Pharmacokinetics and Quantitative EEG Study of CX-8998 in Adolescents and Young Adults With Generalized Epileptic Syndromes With Absence Seizures
This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4- dose-titration treatment period to dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.
Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures.
A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.
Stereotactic Laser Ablation for Temporal Lobe Epilepsy -SLATE-
The SLATE study is a prospective, single-arm, multicenter study. The study is being conducted to evaluate the safety and efficacy of the Visualase® MRI Guided Laser Ablation System.
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Epilepsy
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy
Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults?
The secondary objectives of this study are to investigate the: Prognostic capacity of serum S100B levels to predict seizure recurrence. B) Association between the variation (%) of serum S100B levels between first seizure episode and scheduled follow-up (D14-D28) and seizure recurrence. Correlation of S100B with IL-1b, IL-6, NSE serum levels ...
